Close
What would you like to look for?
Site search

22 November 2021

RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company, has launched its Level 1 American Depositary Receipt ("ADR") program in the United States. As of 18 November 2021, ADRs may be traded over the counter. Relief's ADR program complements its existing primary listing of shares on the SIX Swiss Exchange. J.P. Morgan has been appointed as the depositary bank for the ADR program.

VISCHER advised Relief on the Swiss legal aspects under this ADR program. The VISCHER team led by partner Dr. Robert Bernet (Corporate/M&A) comprised Dr. Peter Kühn (Counsel, Corporate/M&A), Christian Schneiter (Senior Associate, Corporate/M&A) and Christoph Niederer (Partner, Tax).

Categories: Mergers & Acquisitions, Tax

You are currently offline. Some pages or content may fail to load.